Looking to publish in Blood Cancer Journal? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowBlood Cancer Journal is a peer-reviewed fully open access journal dedicated to publishing articles related to hematologic malignancies and related disorders.
Looking to publish in Blood Cancer Journal? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Blood Cancer Journal accepts the following article types. Click on an article type to view submission instructions.
Article
Review Article
Current Treatment Algorithm
Correspondence
Recent Publications
Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia
Stephen P. Martindale, Roberta Santos Azevedo, Drew A. Harrison, Bethany Tesar, Winnie Nguy, Miranda Stiegler, Valeria Ferre, Vanessa Rai, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Stacey M. Fernandes, John-Hanson Machado, Binu Kandathilparambil Sasi, Aishath Naeem, Christopher J. Ott, Jennifer R. Brown
Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia
Giuseppe G. Loscocco, Fnu Aperna, Moazah Iftikhar, Priyansh Faldu, Masooma S. Rana, Amritpal Singh, Tiziano Barbui, Paola Guglielmelli, Alessandro M. Vannucchi, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma
Jiadai Xu, Jing Li, Yuhong Ren, Luya Cheng, Zhixiang Cheng, Jingli Zhuang, Yang Ke, Shiyang Gu, Yian Zhang, Feifei Chen, Rupan Gao, Panpan Li, Yaqin Xiong, Peng Liu
Genomic landscape, clinical correlates and prognostic implications of U2AF1 mutation subtypes in myelodysplastic neoplasms
Zefei Bao, Bing Li, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Yujiao Jia, Lijuan Pan, Qingyan Gao, Meng Jiao, Jinqin Liu, Chengwen Li, Qi Sun, Zhijian Xiao
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström’s Macroglobulinemia
Maria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, Abigail L. Peachey, Amanda Kofides, John Hatcher, Andres Ramirez Gamero, Alberto Guijosa, Guang Yang, Hao Sun, Shirong Liu, Christopher J. Patterson, Kirsten Meid, Catherine Flynn, Ruben D. Carrasco, Andrew R. Branagan, Shayna R. Sarosiek, Jorge J. Castillo, Kenneth C. Anderson, Nikhil Munshi, Steven P. Treon, Zachary R. Hunter
Frequently asked questions
How long does it take to publish?
Reviewers are given 14 days from acceptance to submit their reports. Revision requests are used when authors can address concerns in six months or less. Accepted articles are published immediately as an Article in Press. Proof corrections must be returned within 48 hours of receipt.
Reformat to Blood Cancer Journal using Livewrite PremiumIs a cover letter required?
A cover letter is required. It should include the corresponding author's affiliation and contact information, explain the importance of the work and its suitability for the journal's readership, confirm originality and exclusive submission, include previous reviewer comments if the manuscript was considered elsewhere, and include a Competing Interests statement.
Reformat to Blood Cancer Journal using Livewrite PremiumWhat are the publication costs?
An article processing charge is required. Original Research: £3690.00/$5490.00/€4390.00; Letter / Correspondence / Comment: £1215.00/$1675.00/€1515.00, subject to VAT or local taxes where applicable.
Reformat to Blood Cancer Journal using Livewrite Premium